Attovia Therapeutics

Attovia Therapeutics

Biotechnology Research

Fremont, California 2,908 followers

Creating medicines for immune-mediated disease based on Attobody®, a novel biparatopic nanobody platform.

About us

Attovia is creating a pipeline of biotherapeutics with an initial focus on immune-mediated disease and oncology. We leverage ATTOBODY, a novel biologics platform, to generate small format biparatopic binders that unlock the spatial aspect of target engagement. The biparatopic binding mode of ATTOBODIES translates to picomolar affinity with glue-like off-rates, exquisite specificity, and accelerated target internalization. Their small format and modularity offer fast tissue penetration, ease of engineering into bispecifics, and tunable half-life from hours to weeks. Collectively, these properties of ATTOBODIES expand the addressable target and epitope universe across disease areas and can offer stronger efficacy, faster speed to response, and an improved safety profile compared to traditional approaches. By utilizing our ATTOBODY technology, we will develop novel medicines that target unaddressed elements of disease, as well as offer better efficacy and tolerability. We envision a world where no patient is left behind.

Industry
Biotechnology Research
Company size
11-50 employees
Headquarters
Fremont, California
Type
Privately Held
Founded
2023

Locations

  • Primary

    47071 Bayside Pkwy

    Suite 100

    Fremont, California 94538, US

    Get directions

Employees at Attovia Therapeutics

Updates

Similar pages

Funding